Brief: Citius Pharmaceuticals Reports Productive FDA Type C Meeting
25/11/2024 13:21
Nov 25 (Reuters) - Citius Pharmaceuticals Inc CTXR.O :
* CITIUS PHARMACEUTICALS REPORTS PRODUCTIVE FDA TYPE C
MEETING TO
DISCUSS PHASE 3 MINO-LOK® PROGRAM AND PATHWAY TO APPROVAL
Source text: ID:nPn90KftDa
Further company coverage: CTXR.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Citius Pharmaceuticals
See all newsCitius Pharmaceuticals Q2 revenue rises on LYMPHIR launch
Citius Pharmaceuticals reports first revenue of $3.9 mln
Brief: Citius Oncology Expands International Distribution Of Lymphir™ To European Union Through Exclusive Agreement With Uniphar
Brief: Citius Pharmaceuticals, Inc. Reports Fiscal Year 2025 Financial Results And Provides Business Update
Brief: Citius Oncology Announces $18 Million Concurrent Registered Direct Offering And Private Placement Priced At-The-Market Under Nasdaq Rules